Neovasc Soars 17% as Data Showed Neovasc Reducer ‘Very Safe’ in Significantly Lowering Angina Severity

Shares of Neovasc (NVCN), a developer of minimally invasive transcatheter mitral valve replacement technologies, surged 17% intraday after the company said Monday results from a study undertaken to assess the safety and effectiveness of the Neovasc Reducer showed that the treatment was “very safe and significantly reduced the severity of angina.”

In the published study, the safety and effectiveness of the reducer, a CE-Marked medical device designed for the treatment of refractory angina, was evaluated using a real-world cohort of 141 patients in three medical centers in Milan, Tel Aviv and Antwerp, according to a statement.

The investigator demonstrated that the treatment reduced the severity of angina as measured by the Canadian Cardiovascular Society (CCS) classification from a mean baseline of 3.05±0.53 to 1.63±0.98 at follow-up, with p<0.001. Overall, results show that 81% of the patients experienced improvement in their angina severity by at least one CCS class, and 45% of the patients became free of any limiting angina as they improved by two or more grades in their CCS class. All parameters of quality of life as measured by the Seattle Angina Questionnaire improved significantly, with p <0.001. These benefits translate into a significant reduction in the mean number of anti-ischemic drugs prescribed.